CA
RGLS

Continuum Advisory’s Regulus Therapeutics RGLS Stock Holding History

Continuum Advisory’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-300
Closed -$474 – 1881
2024
Q4 		$474 Hold
300
– – ﹤0.01% 1742
2024
Q3 		$450 Buy
+300
New +$496 ﹤0.01% 1811

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Continuum Advisory's RGLS Position: Q1 2025 in Review

Continuum Advisory sold out of Regulus Therapeutics (RGLS) in Q1 2025, closing a stake of 300 shares — an estimated $474 sold.

Continuum Advisory first reported a position in RGLS in Q3 2024 and held it in 2 quarters. The position peaked at $474 in Q4 2024. 75 funds tracked by Wall St. Rank hold RGLS as of Q1 2025.

  • Continuum Advisory reported no remaining Regulus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Continuum Advisory sold 300 Regulus Therapeutics shares in Q1 2025, an estimated $474.
  • Continuum Advisory first reported a position in Regulus Therapeutics in Q3 2024 and held it in 2 quarters.
  • Continuum Advisory's Regulus Therapeutics position peaked at $474 in Q4 2024.
  • 75 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2025.

Based on Continuum Advisory's 13F filing for Q1 2025, filed 23 Apr 2025.